

Application of PCSK9 Inhibitors in Practice Part 2: The Patient Experience

Tina M. Kaufman, Bruce A. Warden, Jessica Minnier, Joshua R. Miles, P. Barton Duell,
Jonathan Q. Purnell, Cezary Wojcik, Sergio Fazio, Michael D. Shapiro

Abstract: PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are set to revolutionize the treatment of hypercholesterolemia in the management of atherosclerotic risk, but numerous reports have detailed unprecedented barriers to access for these drugs. To overcome these challenges, our group created a model to facilitate provision of this new therapy for patients who qualify according to Food and Drug Administration criteria. This report details the real-world follow-up experience of PCSK9i use in a large patient cohort structured to ensure rigor in data collection, analysis, and interpretation. The 271 patients approved and actively followed in our PCSK9i clinic between July 2015 and August 2018 represent a 97% approval rate from insurance, with 28% of prescriptions requiring at least one appeal. Over 50% of patients were statin intolerant. On average, there was a median lapse of 15 days between initial visit and insurance approval. PCSK9i therapy was affordable for most patients, with an average monthly out-of-pocket expense of \$58.05 (median \$0). Only 2.3% of patients were unable to initiate or continue therapy because of cost. Reductions from baseline in LDL (low-density lipoprotein) cholesterol and Lp(a) (lipoprotein [a]) were comparable to published reports with median reductions of 60% and 23% at 1 year, respectively. PCSK9i therapy was well-tolerated overall, though 9% of patients reported adverse events, and 5% of patients discontinued due mostly to musculoskeletal and flu-like symptoms. Our practice model demonstrates that PCSK9i therapy can be accessed easily and affordably for the majority of eligible patients, resulting in dramatic improvement in lipid profile results. Moreover, our registry data suggest that results from the prospective clinical trials of PCSK9i on LDL and Lp(a) reduction and on tolerability are applicable to a real-world cohort. (*Circ Res.* 2019;124:32-37. DOI: 10.1161/CIRCRESAHA.118.314191.)

Key Words: drug adherence ■ LDL-cholesterol ■ lipoprotein(a) ■ PCSK9 ■ PCSK9 inhibitors

Results from landmark clinical outcome trials of PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitors) have confirmed the initial excitement for this class of LDL-C (low-density lipoprotein-cholesterol) lowering agents,¹⁻³ and the statin hypothesis has been supplanted by the LDL hypothesis. Hence, guideline recommendations and consensus statements now endorse the use of PCSK9i as appropriate second or third line agents, or as alternative therapy in cases of complete statin intolerance, for patients with established atherosclerotic cardiovascular disease or familial hypercholesterolemia with persistent hypercholesterolemia.¹⁻³ As evidence supporting their ability to improve cardiovascular outcomes continues to mount, PCSK9i use will undoubtedly continue to expand given the size of the target population.

Prior reports of PCSK9i treatment have provided details from either the clinical trial perspective,⁴⁻⁶ the provider perspective,⁷⁻¹² or the payer and societal perspectives.¹³⁻¹⁸ However, few reports have reflected the patient experience with PCSK9i in clinical use. This is part 2 of a report that initially described the design and implementation of a dedicated

PCSK9i clinic as a means to increase efficiency of referral and access to PCSK9i treatment for patients who meet standard of care indications for this therapy.⁷ The goal of this second report is to outline, from the patient's perspective, a real-world experience with PCSK9i therapy in relation to accessibility of the drug, out-of-pocket expense, side effects, and lipid-lowering efficacy using a rigorously structured cohort.

Methods

This study derives from preplanned analyses of a prospectively designed clinical cohort in which subjects were enrolled in the previously reported PCSK9i clinic of our Center for Preventive Cardiology at Oregon Health & Science University.⁷ Briefly, patients were referred from within Oregon Health & Science University or by outside providers for consultation about appropriateness for referral to the PCSK9i clinic. During the initial PCSK9i visit, a clinical pharmacist and a physician assistant performed a medical history and physical exam that included detailed documentation of current medications, past lipid-lowering therapies (allopathic and naturopathic), reported intolerances or side effects, diagnoses of lipid disorders using insurance-guided documentation requirements, instruction on injection technique, and a prescription for the PCSK9i medication

From the Center for Preventive Cardiology, Knight Cardiovascular Institute (T.M.K., B.A.W., J.M., J.R.M., P.B.D., J.Q.P., S.F., M.D.S.), Department of Family Medicine (C.W.), and OHSU-PSU School of Public Health (J.M.), Oregon Health & Science University, Portland.

Correspondence to Michael D. Shapiro, DO, FACC Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239. Email shapirmi@ohsu.edu

© 2018 American Heart Association, Inc.

Circulation Research is available at <https://www.ahajournals.org/journal/res>

DOI: 10.1161/CIRCRESAHA.118.314191

Nonstandard Abbreviations and Acronyms

IQR	interquartile range
LDL	low-density lipoprotein
LDL-C	LDL-cholesterol
Lp(a)	lipoprotein (a)
PCSK9i	protein convertase subtilisin/kexin type 9 inhibitors

in appropriately selected patients. The PCSK9i prescription was sent to our specialty pharmacy to process and initiate an electronic prior authorization, which was then completed by either the physician assistant or clinical pharmacist. Once approved, the PCSK9i prescription was routed to the preferred pharmacy and the clinical pharmacist followed up with the patient to review medication cost, injection technique, potential side effects, and timeline for follow-up lipid testing. Follow-up with the physician assistant was scheduled for 6 weeks (within 5 days from the third injection), 6 months, and every 6 months thereafter. A blood sample was also collected before initiation of therapy (baseline). Measurement of plasma lipid and Lp(a) (lipoprotein [a]) concentrations was performed as described previously.¹⁹

Statistical Methods

Continuous measurements were summarized with means and SDs for normally distributed data and as medians and interquartile range (IQR) for nonnormally distributed parameters. Categorical variables were summarized with counts and percentages. Time to approval and time to injection were compared across time intervals with a 1-sided permutation test of the null hypothesis that median time did not change or increased versus alternative hypothesis that median time decreased over the course of our 3-year experience. A 2-factor repeated measures ANOVA was performed to test for differences in LDL and Lp(a) across dose/drug and time points.

Results

The cohort consists of 271 patients approved and actively treated with a PCSK9i. The average age was 61.8 years and the study population was equally divided between men and women (Table 1). Nearly half of the cohort (46%) had atherosclerotic cardiovascular disease as qualifying diagnosis, whereas familial hypercholesterolemia alone or in combination with atherosclerotic cardiovascular disease made up the remaining indications (26% and 28%, respectively; Table 1). Fifty-three percent of subjects in this cohort were deemed statin intolerant (unable to tolerate at least 2 statins, one at the lowest therapeutic daily dose). Among patients with familial hypercholesterolemia, 46% were statin intolerant.

The approval rate for PCSK9i was 97% overall, with 29% of patients requiring at least one insurance appeal before approval. The median time to approval was 15 days, whereas the median time to first injection was 38 days. Both timelines were significantly reduced over the 3-year experience as the PCSK9i workflow was optimized (Table 5).

After insurance approval, the vast majority of patients successfully gained affordable access to PCSK9i, with only 2.3% unable to initiate or continue therapy because of cost (all of whom were Medicare patients). Among the entire cohort, the monthly average insurance copay was \$235.93 (median \$182.22, IQR \$28.50, \$374.75), but these were reduced to an average actual monthly patient out-of-pocket expense of \$58.05 (median \$0, IQR \$0–8.30) because of some form

Table 1. Baseline Characteristics for the PCSK9 Inhibitor Therapy Cohort (N=271)

Age (years±SD)	61.8±10.9
Sex	
Male, N (%)	135 (49.8%)
Female, N (%)	136 (50.2%)
Familial hypercholesterolemia (FH), N (%)	
Without known ASCVD, N (%)	71 (26%)
With ASCVD, N (%)	76 (28%)
ASCVD* only (includes CAD), N (%)	124 (46%)
Asymptomatic ASCVD (CACS/CCTA/ICA), N (%)	42/200 (21%)
Mean CACS in Agatston units±SD	767.9±918.7
Median CACS in Agatston units (IQR)	496.9 (IQR 264.0–938.7)
Heart transplant, N (%)	6 (2%)
LDL in mg/dL (Mean ± SD)	
ALL (N=262)	141.1±56.5
ASCVD only (N=121)	124.9±37.8
FH without known ASCVD (N=66)	167.6±78.5
FH + ASCVD (N=75)	143.7±49.6
Lipoprotein (a) in mg/dL (N=239)	
Mean ±SD	67.10±76.5
Median (IQR)	37.0 (IQR 12.0–97.0)
Range	2.0–480.0
Current medication use at time of PCSK9i approval, N (%)	
High-intensity statin	82 (30%)
Moderate-intensity statin	29 (11%)
Low-intensity statin	16 (6%)
Statin intolerant†	144 (53%)
Statin monotherapy	31 (11%)
Ezetimibe monotherapy	72 (27%)
Statin+ezetimibe	92 (35%)
BAS	33 (12%)
Triple therapy‡	26 (10%)
No prescription medications	67 (25%)
Supplemental therapy	48 (18%)

ASCVD indicates atherosclerotic cardiovascular disease; BAS, bile acid sequestrants; CACS, coronary artery calcium score; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; ICA, invasive coronary angiogram; IQR, interquartile range; and PCSK9i, protein convertase subtilisin/kexin type 9 inhibitors.

*Atherosclerotic cardiovascular disease (includes diagnosis of coronary artery disease by imaging as well).

†Unable to tolerate the lowest therapeutic daily dose.

‡Triple therapy = statin+ezetimibe+bile acid sequestrant.

of financial assistance (Table 2). For commercially insured patients, monthly average insurance copays were \$221.65 (median \$125), but these were reduced to a monthly patient out-of-pocket expense of \$6.32 (median \$0, IQR \$0–5) with the use of a copay card (for which 74% of commercially insured

Table 2. Cost to Patient for PCSK9 Inhibitor Therapy

	Overall	Commercial Insurance	Medicare	Medicaid
Percent of Patients, N (%)	269	119 (44%)	135 (50%)	15 (6%)
Insurance copay (\$)				
Average (\pm SD)	\$235.93 (\pm 248.52)	\$221.65 (\pm 276.49)	\$272.53 (\pm 221.39)	\$6.05 (\pm 20.74)
Median (IQR)	\$182.22 (28.50, 374.75)	\$125 (30, 300)	\$300 (56.37, 390)	\$0 (0, 0)
Range	\$0–1170	\$0–1170	\$0–1150	\$0–75
Patient out-of-pocket expense (\$)				
Average (\pm SD)	\$58.05 (\pm 135.17)	\$6.32 (\pm 35.45)	\$111.11 (\pm 174.22)	\$6.05 (\pm 20.74)
Median (IQR)	\$0 (0, 8.30)	\$0 (0, 5)	\$5 (0, 250)	\$0 (0, 0)
Range	\$0–1150	\$0–100	\$0–1150	\$0–75
Using copay card (%)		74%	N/A	N/A
Financial assistance program, N (%)	54, (20%)	4, (3%)	46, (34%)	...
Unable to start or continue because of cost	2.3% (all Medicare)			

IQR indicates interquartile range; and N/A, not applicable.

patients qualified). Unfortunately, Medicare and Medicaid patients are prohibited from using copay cards. The only financial assistance programs available to Medicare patients are manufacturer-derived patient assistance programs, such as Amgen Safety Net and Sanofi PASS (Patient Assistance Support) programs.^{20,21} Medicare beneficiaries had an average insurance copay of \$272.53 (median \$300, IQR \$56–390), reduced to a patient out-of-pocket expense of \$111.11 (median \$5, IQR \$0–250) with use of patient assistance programs

(10% of Medicare patients received PCSK9i free of charge; Table 2). Finally, Medicaid insured patients had a copay and actual out-of-pocket expense of \$6.05 (median \$0, IQR \$0–0) per month (Table 2). Within the entire cohort, 77% of patients paid <\$10 monthly for PCSK9i therapy. Two Veteran Administration patients were excluded from the cost analysis given that all Veteran Administration patients are required to have their prescriptions written by Veteran Administration providers.

Table 3. Lipid Lowering Response to PCSK9 Inhibitor Therapy

	% Change After Third Injection	% Change After 6 mo	% Change After 1 y
LDL-C Lowering After PCSK9 Inhibitor Therapy			
Alirocumab 75 mg			
Median (IQR)	–52% (–39, –62)	–59% (–47, –72)	–56% (–46, –68)
Alirocumab 150 mg			
Median (IQR)	–49% (–46, –57)	–55% (–40, –72)	–53% (–44, –68)
Evolocumab 140 mg			
Median (IQR)	–65% (–50, –78)	–64% (–49, –78)	–61% (–54, –67)
Overall			
Median (IQR)	–57% (–45, –71)	–61% (–48, –75)	–60% (–48, –75)
Lipoprotein (a) Lowering After PCSK9 Inhibitor Therapy			
Alirocumab 75 mg			
Median (IQR)	–12% (0, –27)	–23% (–12, –40)	–25% (–13, –39)
Alirocumab 150 mg			
Median (IQR)	–12% (–9, –16)	–15% (–9, –21)	–18% (–12, –25)
Evolocumab 140 mg			
Median (IQR)	–14% (0, –31)	–25% (–11, –43)	–18% (0, –35)
Overall			
Median (IQR)	–13% (0, –29)	–23% (–10, –38)	–23% (–9, –38)

Patients were excluded from this analysis if they changed from 1 PCSK9 inhibitor to another. IQR indicates interquartile range; LDL-C; low-density lipoprotein-cholesterol; and PCSK9; protein convertase subtilisin/kexin type 9.

Table 4. Side-Effects Reported at Least Once During PCSK9 Inhibitor Treatment (N=271)

Musculoskeletal symptoms	22 (8.1%)
Injection site reactions	16 (5.9%)
Problems with injection technique	15 (5.6%)
Flu-like symptoms	15 (5.5%)
Fatigue	9 (3.3%)
Nasopharyngitis	8 (3.0%)
GI symptoms	5 (1.8%)
Headache	5 (1.8%)
Cognitive issues	4 (1.5%)
Dizziness	3 (1.1%)
Erectile dysfunction	2 (0.7%)
Depression	2 (0.7%)
Hot flashes	1 (0.4%)
Discontinuation rates because of side effects	13 (5%)

Of the 13 patients who discontinued therapy because of side effects, the reasons cited were: myalgias (4); flu-like symptoms (3); cognitive issues (2); depression (1); fatigue (1); diarrhea (1); dermatologic (1).

Aggregated across product and dose, the median percent reduction in LDL-C and Lp(a) after 12 months of therapy were 60% and 23%, respectively (Table 3), consistent with results reported in controlled clinical trials.⁴⁻⁶ It is noted that while LDL-C reduction reached maximum efficacy at 6 weeks, Lp(a) reduction was 12% at 6 weeks and reached maximum efficacy (25%) at 12 months. The incidence of reported adverse effects was low (Table 4). Musculoskeletal symptoms and injection site reactions were the most common side effects (8.1% and 5.9%, respectively). Twenty-eight

percent of subjects reported at least one side effect at some point during PCSK9i therapy. However, only 5% of the cohort discontinued therapy because of adverse events (Table 4), whereas 2.3% of patients either discontinued or did not start therapy because of cost. The remaining 92.7% of patients successfully continued treatment throughout the duration of our assessment.

Discussion

We previously described the design of a dedicated PCSK9i clinic model to overcome the formidable challenges to access PCSK9i therapy for patients meeting Food and Drug Administration indications.⁷ Here we shift the focus to the patient perspective, and in doing so highlight the value of our now established model for management of PCSK9i treatment. Overall, the implementation of a dedicated PCSK9i clinic has resulted in a 97% rate of drug approval, far higher than the national average approval rate of 40% to 50% reported in the literature.⁹⁻¹² Financial burden for patients was reasonable in most cases, with an average monthly out-of-pocket expenditure of \$57 and discontinuation rates because of cost of only 2.3%. This high-approval rate and low-patient out-of-pocket expenditure stands in contrast with media reports and the peer-reviewed literature in which about a third of patients were reported never filling PCSK9i prescriptions primarily because of cost.¹⁰ Moreover, within our model, we noted dramatic improvements in time from initial visit to drug approval and time from initial visit to first injection, with median times of 44 and 64.5 days before implementation of our program, dropping to current times of 15 and 17 days, respectively. While this enhanced efficiency was partially because of the addition of dedicated personnel, it was largely accounted for by the adoption of a formalized and standardized evaluation process that ensured

Table 5. Time to Approval of PCSK9 Inhibitors

Clinical Team Members	N	Visit With Provider to Receipt of Approval Letter (d)		
		Average time (±SD)	Median (IQR)	Range
RN and physician	81	56.1 (±47.6)	44 (18, 78)	4–196
APP, clinical pharmacist and MA*	138	19.9 (±23.4)	12 (7, 23.75)	0–151
APP, clinical pharmacist, MA, and specialty pharmacy services†	26	8 (±9.3)	6 (2.5, 7)	1–35
Overall	245	30.6 (±37.3)	15 (7, 35)	0–196
Time to First Injection of PCSK9 Medications				
		Visit With Provider to First Injection (d)		
Clinical Team Members		Average Time (±SD)	Median (IQR)	Range
RN only	92	75.4 (±54.1)	64.5 (35.75, 94.5)	14–319
APP, clinical pharmacist and MA*	134	45.4 (±55.8)	31 (22, 49.75)	8–557
APP, clinical pharmacist, MA, and specialty pharmacy services‡	17	22.4 (±19.0)	17 (8, 29)	3–70
Overall	243	55.2 (±55.8)	38 (24, 68.5)	3–557

APP indicates advanced practice provider; IQR, interquartile range; MA, medical assistant; RN, registered nurse.

*P<0.001 vs RN only.

†P<0.001 vs APP, clinical pharmacist, MA.

‡P=0.0016 vs APP, clinical pharmacist, MA.

proper documentation of insurance criteria for coverage, transitioning from a paper to electronic format for insurance application, and, with time, improved understanding and communication with insurance companies in response to denials. Importantly, the observed improvement in time to medication approval was related to the process improvements that we implemented rather than a generalized relaxation in barriers to access, which only a few payers have adopted recently. While not directly assessed in this study, we anticipate that the improved efficiency and access to PCSK9i translates into increased patient satisfaction and potentially improved clinical outcomes, as prior reports have highlighted increased risk of atherosclerotic events while high-risk patients await the lengthy approval process.²²

Consistent with the clinical trial evidence, our real-world cohort recapitulates the LDL-C lowering efficacy and tolerability of the PCSK9i class. Interestingly, 53% of the patients in our PCSK9i cohort were completely statin intolerant. Three recent European cohorts also reported a $\approx 50\%$ rate of statin intolerance in patients referred for PCSK9i.^{23–25} This is remarkable because it demonstrates that the availability of an official indication for statin intolerance (as granted by the European Medicines Agency) does not seem to influence the proportion of statin-intolerant patients receiving PCSK9i therapy. Interestingly, while LDL-C reduction reached peak efficacy by 6 weeks of therapy, Lp(a) reduction was 12% at 6 weeks, and 25% at 12 months. This suggests that the Lp(a) lowering associated with PCSK9i is not simply mediated by LDL receptor upregulation.

As clinicians strive to optimize residual atherosclerotic risk reduction, our experience outlines an effective strategy to establish a PCSK9i clinic that efficiently improves patient access to affordable and highly efficacious treatment with PCSK9i. The keys to success in this PCSK9i clinic model are optimal staffing, appropriate patient identification, use of standardized protocols for data acquisition, continued pursuit of payer approval despite initial denials, and education of patients on cost-saving programs. We show that PCSK9i therapy is accessed easily and affordably by the majority of eligible patients, and that results from prospective clinical trials of PCSK9i on LDL and Lp(a) reduction are applicable to this real-world cohort.

Acknowledgments

We gratefully acknowledge Kelsey Kyle, medical assistant, and Victoria Simeon, registered nurse, for their help in the daily operations of the PCSK9i clinic.

Sources of Funding

The study was partially supported by a development grant from the Knight Cardiovascular Institute. No commercial entities were involved in the development of the program or in the design, interpretation, discussion, or article preparation of this study. Dr Shapiro is supported by National Institutes of Health K12HD043488.

Disclosures

M. Shapiro reports advisory work for Novartis, Amarin, and Esperion. S. Fazio reports advisory work for Kowa, Esperion, Amgen, Aegerion, Akcea, and Amarin. J. Purnell reports advisory work for Novo Nordisk. P. Duell reports research grants from Regeneron,

Esperion, and Retrophin, and advisory work for Akcea, Daichii-Sankyo, Esperion, Kastle, Regeneron, RegenxBio, and Retrophin. The other authors report no conflicts.

References

- Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA. Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association. *J Clin Lipidol*. 2017;11:880–890. doi: 10.1016/j.jacl.2017.05.001
- Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol*. 2017;70:1785–1822. doi: 10.1016/j.jacc.2017.07.745
- Landmesser U, Chapman MJ, Stock JK, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. *Eur Heart J*. 2018;39:1131–1143. doi: 10.1093/eurheartj/ehx549
- Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
- Ridker PM, Revkin J, Amarencu P, et al; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. *N Engl J Med*. 2017;376:1527–1539. doi: 10.1056/NEJMoa1701488
- Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome [published online November 7, 2018]. *N Engl J Med*. doi: 10.1056/NEJMoa1801174. <https://www.nejm.org/doi/full/10.1056/NEJMoa1801174>.
- Kaufman TM, Duell PB, Purnell JQ, Wójcik C, Fazio S, Shapiro MD. Application of PCSK9 inhibitors in practice: challenges and opportunities. *Circ Res*. 2017;121:499–501. doi: 10.1161/CIRCRESAHA.117.311532
- Payer Dynamics. Symphony Health Solution's IDV; based on 3/31/2016 data. 2016. <https://symphonyhealth.com/wp-content/uploads/2017/03/PCSK9-Inhibitors-Payer-Dynamics-Feb-2017.pdf>. Accessed September 5, 2018.
- Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. *Clin Cardiol*. 2017;40:243–254. doi: 10.1002/clc.22713
- Navar AM, Taylor B, Mulder H, Fievtz E, Monda KL, Fievtz A, Maya JF, Lopez JAG, Peterson ED. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. *JAMA Cardiol*. 2017;2:1217–1225.
- Knowles JW, Howard WB, Karayan L, Baum SJ, Wilemon KA, Ballantyne CM, Myers KD. Access to nonstatin lipid-lowering therapies in patients at high risk of atherosclerotic cardiovascular disease. *Circulation*. 2017;135:2204–2206. doi: 10.1161/CIRCULATIONAHA.117.027705
- Hess GP, Natarajan P, Faridi KF, Fievtz A, Valsdottir L, Yeh RW. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. *Circulation*. 2017;136:2210–2219. doi: 10.1161/CIRCULATIONAHA.117.028430
- Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. *JAMA*. 2016;316:743–753. doi: 10.1001/jama.2016.11004
- Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K, Michos ED, Bittner VA, Petersen LA, Ballantyne CM. Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): insights from the department of veterans affairs. *Circulation*. 2017;135:2572–2574.
- Mark DB, Schulman KA. PCSK9 inhibitors and the choice between innovation, efficiency, and affordability. *JAMA*. 2017;318:711–712. doi: 10.1001/jama.2017.8907

16. Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial. *JAMA Cardiol.* 2017;2:1369–1374. doi: 10.1001/jamacardio.2017.3655
17. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER Trial. *JAMA.* 2017;318:748–750. doi: 10.1001/jama.2017.9924
18. Hlatky MA, Kazi DS. PCSK9 inhibitors: economics and policy. *J Am Coll Cardiol.* 2017;70:2677–2687. doi: 10.1016/j.jacc.2017.10.001
19. Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S. PCSK9 association with lipoprotein(a). *Circ Res.* 2016;119:29–35. doi: 10.1161/CIRCRESAHA.116.308811
20. Amgen Safety Net Foundation. Patient Assistance Program. <https://www.amgensafetynetfoundation.com>. Accessed September 25, 2018.
21. Sanofi PASS. Patient Assistance Program. <https://www.praluenthcp.com/starting-praluent/insurance-coverage>. Accessed September 25, 2018.
22. Baum SJ, Chen CC, Rane P, Patel J, Maya J, Harrison D, Yurgin N, Wade R, Desai N. Cardiovascular risk in patients denied access to PCSK9i therapy. *J Am Coll Cardiol.* 2017;71(suppl 11):A1760.
23. Kassner U, Hollstein H, Grenkowitz T, et al. PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting. *Eur Heart J.* 2018;39(suppl):1041.
24. Ray KK, Bruckert E, Annemans L, et al. Characteristics of patients prescribed evolocumab in Europe. Does clinical use match clinical guidelines? *Eur Heart J.* 2018;39(suppl):343.
25. Parhofer KG, Von Stritzky B, Paar WD, et al. PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data. *Eur Heart J.* 2018;39(suppl):1104.